

OUR SUPPORT ENABLES







Cancer, 4,500 participants



Cancer, 3,500



Scotiabank Road Hockey 145 teams



3,200 participants



Golf to Conquer Cancer,



Through two Chinese



third party events





our generous donors

* NET PROCEEDS



- Message from our leaders
- Building the vision to enable Future Care Now
- Team #ConquerCancer
- **Building our Cancer Centre** for the future
- Advancing world-leading cancer research
- Future Care Now: Create Cancer Care - 2030

TURE CARE NOW AT THE PRINCESS MARGARET

17,801

New patients



6,400+

416,400 FT²

3,200

People in Research and Clinical Care Enterprise

230,920

1.097

380



NET FUNDRAISING AND LOTTERY REVENUE (YEAR ENDING MARCH 31, 2019)

- Accelerating artificial intelligence and microbiome research
- Supporting esophageal cancer research
- 2019 Year in review
- Till & McCulloch Society
- Fuelling gynecological cancer research

- **JCB Grant Society**
- Financial summaries: 5-Year overview
- Financial summaries: Fiscal 2019
- Research Chairs
- Foundation Board of Directors
- **UHN Board of Directors** and 2019-23 Strategic Plan

MESSAGE FROMOUR LEADERS



The past year has been one of strategic renewal for our organizations, driven by new leadership and our unwavering commitment to elevate the impact we have in research, education and patient care. Aligned with the Cancer Centre's new vision of Future Care Now: Create Cancer Care 2030 and UHN's vision for A Healthier World, our Foundation launched a bold new vision to elevate the impact our donors have on this next frontier of progress. Future Care Now represents a commitment to deliver the very

best treatments available today, while accelerating discovery of tomorrow's breakthroughs through research at The Princess Margaret and across our global network. We know that by driving to create and deliver Future Care Now, we will Conquer Cancer In Our Lifetime.

The Princess Margaret Cancer Foundation is proud to report \$108.8 million in net fundraising and lottery revenue. This included a \$10.5 million anonymous gift to support Dr. Tak Mak and the Therapeutics Group, as well as



senior Canadian gold mining company Agnico Eagle Mines' \$5 million investment in promising immunotherapy research. We engaged over 4,500 riders and 3,200 walkers in our major events, and launched a new online gaming fundraising program, Quest to Conquer Cancer, which raised over 50% of its revenue from outside Canada. Finally, The Princess Margaret Home Lottery set a new record, with net revenue of \$33.6 million with 34,000 prizes awarded. Funds raised through all of our programs will enable Future Care Now at Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world.

World-leading research and clinical care takes a community - and we are grateful for the generous support of our volunteers, donors, and community members who have made such an incredible impact. Thank you for enabling Future Care Now for patients at The Princess Margaret, across Canada, and around the world. 😢

(Left to right)

Dr. Mary Gospodarowicz, Medical Director, Princess Margaret Cancer Centre

Dr. Aaron Schimmer, Research Director. Princess Margaret Cancer Centre

Janice Fukakusa, Board Chair, The Princess Margaret Cancer Foundation

Michael Burns, President & CEO, The Princess Margaret Cancer Foundation

Brian J. Porter, Board Chair, University Health Network Board of Trustees

Dr. Kevin Smith, President & CEO, UHN



BUILDING THE VISION TO ENABLE FUTURE CARE NOW

Courage is everywhere at The Princess Margaret. It was at the heart of Canada's first \$1 billion healthcare campaign and the launching of the world's largest charitable home lottery. It is within every person who signs up to fundraise for the longest bicycle ride or walk they may ever do. It is in the hearts of our donors who put their trust in our team to transform their gifts into life-saving discoveries and treatments. Courage is in all of us.



OUR MISSION

We enable Future Care Now by raising funds that accelerate cancer research, education and clinical care benefiting patients at The Princess Margaret, across Canada, and around the world.

This year, we challenged ourselves to rethink the role we can play in enabling Future Care Now by developing an ambitious new strategic plan - Strategic Plan 2025: The Roadmap to Enabling Future Care Now. The process was fuelled by over 200 stakeholders, including team members, donors, clinicians, thought leaders and industry experts. We sought to be revolutionary — not evolutionary — in our approach.

Through delivery of this six-year plan, we will elevate the fundraising capacity of our organization to accelerate the groundbreaking research being done every day at one of the top 5 cancer research centres in the world. We will strengthen the impact of donor funds in the fight against cancer at Princess Margaret Cancer Centre and beyond, and deliver on our aspiration to become Canada's most respected charitable foundation where people want to give, work and volunteer.

By enabling Future Care Now, we will advance on our vision, to Conquer Cancer In Our Lifetime.

We believe that the most impactful place in the world that a donor can make an investment in conquering cancer is at The Princess Margaret. Our research team is connected to a global network of scientists and clinicians from over 200 different institutions in over 30 countries. Each year, we attract medical trainees from over 70 institutions around the world, who choose to come to The Princess Margaret to learn from our world-leading scientists, clinicians, and faculty.


When you make a gift to The Princess Margaret, you are fuelling a global network of impact that benefits patients both here at home and around the world. We thank our donors, volunteers, and community members for partnering with us to enable Future Care Now at The Princess Margaret.

The Princess Margaret's Global Network of Impact RESEARCH PARTNERSHIPS GLOBAL CAPACITY UILDING INITIATIVES

COURAGE IS IN ALL OF US Team #CONQUERCANCER



princessmargaret lotto.com





onewalk.ca







golftoconquercancer.ca

* NET PROCEEDS

\$33.6M* Total lottery revenue


\$28.9M Total revenue from flagship events



Total revenue from community events. Thanks to our event organizers, committees, advisory groups, participants, guests and volunteers.















taylorcup.ca



fighttoendcancer.com



thepmcf.ca/events



driveforexcellencegolftournament.ca





In 2018, we began construction on the most significant renovation to our clinical space we have made since The Princess Margaret moved to University Avenue in 1995.

This multi-phase space transformation is modernizing our common patient spaces, optimizing existing space to enable us to care for over 18,000 new patients each year, and advancing translational research to create critical

space to deliver Future Care Now.

This past year, we completed several significant milestones in the project. Our new Gynecologic Oncology Clinic opened on the fifth floor of the Cancer Centre. The bright new space consolidates three outdated spaces into one.

The Warren-Connelly Palliative Care Clinic is also now open on the fifth

floor, which provides more space and resources to better meet the needs of patients and their families.

The entrances at both University Avenue and Murray Street will also include significant visual and accessible upgrades.

Inside the Cancer Centre, enhancements will be made to the main floor lobby, opening up the narrow corridor between the entrances to alleviate congestion.

New art and warm lighting will also be added, along with comfortable new patient lounges.

The newly designed Outpatient Pharmacy is now open on the main floor with a new Patient Lounge, made possible with the support of the Drimmer family.

Other spaces to be transformed include the Cancer Education Library and Magic Castle, as well as the addition of a Digitally Enabled Hub located in the new Foundation space.

(Top) The new Warren-Connelly Palliative Care Clinic.

(Bottom) The new Gynecologic Oncology Clinic.



THE PRINCESS MARGARET'S SPACE TRANSFORMATION IS MADE POSSIBLE THANKS TO THE SUPPORT OF OUR DONORS

Our \$50 million goal will strengthen our commitment to put patients first. Support this campaign: SpaceTransformation.ca

NICHOLAS FIDEI

Nicholas Fidei and his family have made a generous \$2 million donation to the campaign through The Nicholas Fidei Foundation. Fidei, President of Treasure Hill Homes, is a longtime supporter of The Princess Margaret.

"Cancer has touched every family in some way, shape or form and has affected people in my life," says Nicholas Fidei. "It's important that we put as much effort as we can into the disease to give and help and do what we can."



S.O. ASHER CONSULTANTS LTD.

S.O. Asher Consultants Ltd. made a \$1 million gift to the campaign and will have an Educational Lounge on the main floor named in their honour. S.O. Asher develops and manages charity lotteries all around the world, including The Princess Margaret Home Lottery.

"As a long-term partner of The Princess Margaret, we are proud to support them in their goal to Conquer Cancer In Our Lifetime. We are honoured to be part of the Space Transformation Campaign that is committed to improving the experience of every patient, family member and caregiver at Princess Margaret Cancer Centre," says Andy Asher, President & CEO.



LARRY ROSEN AND SUSAN JACKSON

Larry Rosen and his wife Susan Jackson donated \$1 million to the Space Transformation Campaign and will have a beautiful lounge on the main floor named in their honour.

Rosen, Chairman & CEO of Harry Rosen Inc., has sat on the Board of Directors for The Princess Margaret Cancer Foundation for the past nine years. His company has also been a longtime supporter of The Princess Margaret, sponsoring events such as Harry's Spring Run-Off and Golf to Conquer Cancer.

"There's no doubt The Princess Margaret is state-of-the-art in its research and patient care and I think the Space Transformation is an important step to align the environment with the quality of the institution," says Larry Rosen. 💜



Find out more at ThePMCF.ca/transformation Donor lists online: The PMCF. ca/AR2019

\$50 MILLION **CAMPAIGN**

TO ADVANCE **WORLD-LEADING CANCER RESEARCH**



At Princess Margaret Cancer Centre, research is at the heart of everything we do.

As one of the top five cancer research centres in the world, our centre is home to a history of game-changing breakthroughs such as identifying the stem cell and the T-cell receptor, which has changed the way scientists around the world understand and treat cancer. Our international team of scientists are recognized around the world for significant contributions in high impact oncology journals and through their global leaderships in specific areas of cancer research and discovery. Each day, our research team is shaping the future of cancer care.

Together with the Cancer Centre's new Research Director, Dr. Aaron Schimmer, and UHN's Executive Vice-President of Science and Research, Dr. Bradly Wouters, The Princess Margaret Cancer

Foundation is committed to raising crucial funds to support this work.

Enabling world-leading research takes a community, and this past year we were pleased to celebrate the completion of our \$50 million research campaign thanks to the generosity of our donors.

In today's research landscape, government support and grant funding is limited. Our researchers depend on philanthropy to fuel their innovations. The Princess Margaret's researchers consistently leverage donor support so that the impact of every dollar invested in research is more than doubled through matching grants.

The \$50+ million raised during our recent campaign will help to accelerate research at The Princess Margaret and offer more than just hope to cancer patients everywhere. Our work here isn't done. Our fundraising efforts for research will continue to be top priority.

Support cancer research: The PMCF. ca/Research

FUTURE CARE **NOW:**

CREATE **CANCER** CARE -2030

The 2019 Princess Margaret Cancer Centre Strategy, Future Care Now: Create Cancer Care - 2030, outlines the foundational essentials and new strategic priorities that will guide our growing cancer program. Our new priorities are constructed with patients and families at the centre, grounded in co-creating exceptional care experiences for patients and providers, continuing our commitment to excellence in education, and accelerating progress in discovery. The goals and objectives outlined in this plan will be achieved over a number of horizons - some setting the foundation for growth and potential, and others pushing the boundaries of what is possible. 😢

Read the full report: The Princess Margaret.ca/Strategy

NEW STRATEGIC PRIORITIES



SHAPE THE FUTURE OF CANCER CARE

Challenge traditional models of care and create space for new possibilities that enable patients to receive state-ofthe-art care in the right way, time and place.



ADVANCE CANCER CONTROL LOCALLY AND GLOBALLY

Expand our strategic partnerships to heighten cancer as a priority for action and revolutionize how cancer care is organized, delivered and funded.



HARNESS THE POTENTIAL OF DATA SCIENCE

Be at the forefront of inventing and applying novel analytical approaches and predictive models that hold the promise of transforming care, education and research.



DRIVE CANCER DISCOVERY

Build on our rich history of scientific breakthroughs by accelerating discovery across the full spectrum of basic, translational and clinical research.



SUPPORT AND CHAMPION THE NEEDS OF PEOPLE AFFECTED BY CANCER

Enhance clinical care, education and research to better meet the full spectrum of patient and family needs across the cancer care continuum.

\$1 MILLION DONATION FROM TOMCZYK FAMILY TO FUND ARTIFICIAL INTELLIGENCE **AND MICROBIOME** RESEARCH



Fred and Vicki Tomczyk with their grandson, Theo

There are more than 100 trillion microbes in the human body outnumbering normal cells by up to 10 times — and a large proportion of these microbes are in the gut. Disturbances of the gut microbiome have been associated with a number of different diseases, ranging from

inflammatory bowel disease to asthma, and increasingly, cancer.

Researchers at The Princess Margaret are exploring the connection between the microbiome and cancer, especially as they relate to the genetic drivers of cancer and our immune system.

Key programs such as the Tumour Immunotherapy Program (TIP) and the Cancer Genomics Program at The Princess Margaret are at the forefront of cancer research. However, data generated by research programs are traditionally kept in separate databases by different groups and seldom shared as a result.

In response, the Artificial Intelligence and Microbiome (AIM) program was formed in September 2018 to study the microbiome and help researchers mine "big data"

using sophisticated analysis and machine learning algorithms.



AlM's goal in the first year was to obtain data from ongoing microbiome studies and integrate it with other data such as genomics for analysis.

A \$1 million gift from the Tomczyk family is helping to move this research forward.

"Cancer has touched our lives in so many ways," says Vicki Tomczyk. "We want to contribute and encourage the research that will make detection less intrusive, and treatment more precise, for our children and future generations."


Researchers are working with everyone from microbiologists to infectious disease specialists, using technology such as bioinformatics, data science and artificial intelligence to analyze the complex data.

A new trial in head and neck cancer has already begun. Saliva, throat swabs and stool samples are being collected from patients undergoing chemotherapy and radiation to see how the bacteria profiles in their gut and throat correlate with one another and with response to treatment.

Dr. Lillian Siu, Co-Director of TIP, says the next step is to attempt to change the bacterial composition in a patient's gut. This could be done by testing, through clinical trials, the addition of oral probiotics (some of which

contain favourable bacterial strains), or one day, transplanting fecal microbiome from one patient's gut to another.

"It sounds far-fetched, but it's actually not," says Dr. Siu. "People have already started to think about that and we have researchers at The Princess Margaret who are experts in this area. We're collaborating with them on these fronts."



Dr. Lillian Siu, Co-Director, Tumour Immunotherap Program, Princess Margaret Cancer Centre



Donor lists online: ThePMCF.ca/AR2019



A HEARTFELT THANKS AND A HOPE TO HELP OTHERS:

SHASTRI FAMILY

DONATES \$1 MILLION TO CANCER RESEARCH



(Left to right)

Dr. Paul Carroll (Fellow), Terra Shastri (daughter), Etta Shastri, Shiri Shastri and Dr. Gail Darling

Etta Shastri survived cancer. And now she and her husband Shiri, along with their two daughters, are showing their appreciation to The Princess Margaret, where she received treatment, with a \$1 million gift.

It was the summer of 2017 when Etta first knew something was wrong. While spending time with her family at the cottage, she began to feel tired and lethargic. She paid a visit to her family doctor, but didn't think much of her symptoms until a couple of months later when she received a call from the hospital ordering a colonoscopy and gastroscopy.

The tests revealed she had a cancerous lesion on her lower esophagus and had Stage 3 esophageal cancer.

Etta recalls, "I thought, 'I'm just going to beat this.""

With her family by her side, Etta prepared for what came next.


"I was afraid of the journey. I knew it was going to be a long one and it wasn't going to be pleasant."

But when she arrived at The Princess Margaret, she knew she was in good hands.

"When I went in and I met Dr. Gail Darling and Dr. Paul Carroll, we had this instant connection," says Etta.

She underwent surgery, as well as five weeks of chemotherapy and radiation. Etta's CT scans are now clear and she is doing very well.

"I'm just thankful for every day. It changes your whole outlook on life. It gives you something to be grateful for," says Etta.



The family made the decision to support Dr. Darling's work. They hope their gift will help other patients have positive outcomes. Dr. Darling and her colleagues are working to establish a worldleading, comprehensive esophageal cancer research program at The Princess Margaret to further their knowledge, understanding, and treatment of this disease.

Their current program objective is to understand the molecular

characteristics of esophageal cancer in order to develop targeted drugs and create personalized treatment regimens.

"We're grateful for what The Princess Margaret did for my wife and I'm very happy I was able to put in some money (to advance) cancer research," says Shiri.

"It's one way of helping people. If it helps 10 or 12 people to pull through, it's wonderful," adds Etta. 😍 Shiri and Etta Shastri





























- Enbridge Ride to Conquer Cancer
- World's Largest Road Hockey Fundraising Event
- Spin to Conquer Cancer
- Horizons Gala
- Benefit Iftar
- Behind-the-Scenes
- Fight to End Cancer
- Rexall OneWalk to Conquer Cancer
- Doves of Hope









- 10. Journey to Conquer Cancer
- 11. Home Lottery Early Bird prize
- 12. Taylor Cup
- 13. International Women's Day
- 14. Colour to Conquer
- 15. Pink Ribbon Event
- 16. Golf to Conquer Cancer
- 17. Yoga to Conquer Cancer
- 18. Fairchild Chinese Radiothon
- 19. Northern Pass















The Princess Margaret Cancer Foundation created the Till & McCulloch Society to recognize supporters who have cumulatively

contributed \$1M or more to advance cancer research at Princess Margaret Cancer Centre.

(Top, left to right) Dr. Kevin Smith, Sandie Rinaldo and Michael Burns

(Bottom, left to right) Drs. James Till and Ernest McCulloch

Founded in 2015, our Society is named in honour of Dr. James Till, a biophysicist, and Dr. Ernest McCulloch, a haematologist researchers who pioneered stem cell science when they discovered the blood-forming stem cell in the 1960s. This seminal work subsequently led to advance other discoveries in medicine such as bone marrow transplantation.

Like these remarkable scientists. members of the Till & McCulloch Society, through their significant

financial contributions, have helped accelerate cancer research, solidifying The Princess Margaret as one of the top 5 cancer research centres in the world. We are grateful to all of the individuals, families and organizations listed for their vision and passion to help Conquer Cancer In Our Lifetime.

To honour their tremendous support, members of the Society have the opportunity to attend exclusive events with Cancer Centre leadership, and they are the first to receive important updates and information.

In November 2018, the Till & McCulloch Society hosted an intimate cocktail reception to introduce our new leaders, Kevin Smith, President & CEO, University Health Network and Michael Burns, President & CEO, The Princess Margaret Cancer Foundation, to Society members. This lively evening, titled "Meet the CEOs," consisted of a Q&A session moderated by our special guest,



CTV National News Weekend Anchor, Sandie Rinaldo.

Our Lunch with Leaders series continued with inspiring sessions featuring Dr. Gelareh Zadeh, Head, Division of Surgical Oncology, and Dr. Amit Oza, Head, Department of Medical Oncology and Hematology and Co-Director of the Bras Drug Development Program. Dr. Zadeh described the exciting new developments in surgical oncology that are improving the lives of patients here at The Princess Margaret, across Canada and around the world. Dr. Oza provided our members with a thorough overview of the recent clinical and research priorities at The Princess Margaret.

For more information about the Society, please contact Susan Carter, Director, Donor Relations at 416-946-4554 or T&MSociety@thepmcf.ca. 😍



(Left to right) Drs. Mary Gospodarowicz and Daniel Andreae

TILL & MCCULLOCH SOCIETY*

Daniel C. Andreae

The Andrée Rhéaume and Robert Fitzhenry Family Foundation

Susan and Murray Armitage

AstraZeneca Canada Inc.

The Atkinson Charitable Foundation

The Bhalwani Family

Molly and David Bloom

BMO Financial Group

Boehringer Ingelheim (Canada) Ltd.

Maggie Bras and Family

David and Paula Butterfield

CARA Operations Limited

Family of Haji Usman Dawood Choksi CIBC

John and Myrna Daniels

Bob Dorrance & Gail Drummond

Sherry and Edward Drew

The Elia Family

The Elizabeth and Tony Comper

Foundation

Joyce and Philip Epstein

Graham Farquharson

FDC Foundation

Gordon and Donna Feeney

Lia and Nicholas Fidei

Front Street Capital Charitable

Foundation

Janice Fukakusa and Greg Belbeck

Bruce Galloway

Myron and Berna Garron

The Gerald Schwartz & Heather

Reisman Foundation

Peter and Shelagh Godsoe and Family

Mitchell Goldhar

Greenpark Group

The Gucciardi Family

Giovanni & Concetta Guglietti Family

Hoffman-La Roche Ltd.

Hold'em for Life Charity Challenge

I.U.O.E., Local 793

Jack Weinbaum Family Foundation

Janet D. Cottrelle Foundation Jesse & Julie Rasch Foundation

The Allan and Ruth Kerbel Family

Neville and Lorraine Kirchmann The Lewitt Family Foundation

Jon and Nancy Love

Ronald MacFeeters, Sheila MacFeeters, Laura MacFeeters and

Elizabeth Hamilton

John and Gail MacNaughton

Tak Mak Family

Lynn and Robert G. Matthews Margaret and Wallace McCain

Merck Canada Inc.

The Michael Young Family Foundation

Nadir and Shabin Mohamed

Foundation

The O'Neil Foundation

Pancreatic Cancer Canada Foundation

Joan W. Parkes

Nancy Pencer & Family

Pfizer Canada Inc.

The Posluns Family Foundation

RBC Foundation

Nita and Don Reed

RioCan REIT

Richard Rooney and Laura Dinner

The Samuel Family Foundation

Scotiabank

Etta and Shiri (Shri) Shastri

Shoppers Drug Mart

Allan Slaight and Emmanuelle

Gattuso

Slaight Family Foundation

The Strobele Family

Kevin and Sandra Sullivan

Joey and Toby Tanenbaum

Tauba & Solomon Spiro Family

Foundation

Joan and Ken Taylor

TD Bank Group

J.W. Nevil Thomas and Family

Edward G. Thompson and Family

Fredric and Vicki Tomczyk

Tony and Wendy Traub

Warren-Connelly Families

The WB Family Foundation

The Westaway Charitable Foundation

Robert and Gerardina Wharton and Family

Anonymous (9)

*Names appear with express permission received from the donor

THE PARKES FAMILY DONATES

\$1M TO GYNECOLOGICAL

RESEARCH IN HONOUR OF THEIR LATE WIFE AND MOTHER



Joel and Joan Parkes first met as biochemistry students working in a Toronto research lab in 1965 and fell in love.

"I was moonstruck for the first time in my entire life," recalls Joel. "The more we talked, the more we looked forward to seeing each other and talking more. That's how it blossomed over the years."

The pair eventually married and spent 46 years together before Joan passed away in 2018, after a twoyear battle with cancer.

Joan was first diagnosed with squamous cell carcinoma in 2016 and received radiation treatment at Princess Margaret Cancer Centre.

"She received the best possible treatment she could have ever had at The Princess Margaret," says Joel.

In late 2017, Joan and Joel found out the cancer had spread. She died shortly after at the age of 76.

It was Joan's wish to give back to the Cancer Centre where she was treated.

With her blessing, her family donated \$1 million to The Princess Margaret. The money will support gynecological research in squamous cell cancers under the direction of Dr. Stephanie Lheureux, Gynecology Site Lead at The Princess Margaret.

Dr. Lheureux put together a new working group to review and fund projects in this area.



"This is an incredible coincidence and timely. It all fell into place very nicely," says Joel.

"The gynecological site group is very grateful for this generous donation," says Dr. Lheureux. "The funds will support our team in fulfilling Joan's wishes to improve the care and quality of life for women diagnosed with squamous cell carcinoma and advance research."

A lab at The Princess Margaret Cancer Research Tower has also been named in Joan's honour - The Joan Parkes Research Laboratory.

It's a fitting tribute considering Joan spent her career working in a lab, according to Joel. It's also the place where their lifelong love began.

"It's a whole life cycle coming around again," says Joel. 💜

(Left to right)

Joel Parkes and Dr. Stephanie Lheureux, Clinician Investigator, BRAS Drug Development Program and Medical Oncologist and Gynecology Site Lead, Princess Margaret Cancer Centre

JCB GRANT SOCIETY

Membership in the JCB Grant Society is offered to donors who have included The Princess Margaret in their will or have made a gift of life insurance. For more information, contact Genane Peniak, genane.peniak@thepmcf.ca or 416-946-2295.





LEAVING A LEGACY: MARGARET LYNCH **ON GIVING BACK** TO THE PLACE THAT SAVED HER LIFE



(Left to Right) The late Dr. Hans Messner and Margaret Lynch at the 2008 Ride to Conquer Cancer

Thirty years ago, Margaret Lynch received an experimental bone marrow transplant, a first in Canada, at Princess Margaret Cancer Centre.

Today, she is healthy and thriving, dedicated to giving back to the place that saved her life.

Margaret's involvement with The Princess Margaret runs deep. She's cycled more than 200km to raise funds for cancer research nine times. She also worked for the Foundation supporting its fundraising efforts. She has also left a Legacy Gift in her will.

"I know firsthand that supporting The Princess Margaret will further cancer research and get us closer to a world without cancer," says Margaret, who was only 30 years old when she was diagnosed with a rare form of acute leukemia in January 1988.

After a combination of chemotherapy and other drugs proved unsuccessful, Margaret was left with few options.

The Princess Margaret was only performing transplants for patients in remission at the time but Dr. Hans Messner, who pioneered stem cell transplantation at The Princess Margaret, agreed to try the procedure. It was the first time this

would ever be done at The Princess Margaret and in the country. With her sister as her donor, Margaret received her transplant later that year in May.

Eighteen days later, she walked out of the isolation room with no traces of cancer left in her body.

She didn't share her story until two decades later, when she took part in the Enbridge Ride to Conquer Cancer in 2008. When she reached the finish line, Dr. Messner was there, waiting for her with a big smile on his face.

"It was just an incredible moment to think that 20 years earlier we were in my hospital room. There's no way we could have imagined this."

Dr. Messner passed away in July 2018 from bladder cancer and Margaret helped to honour him with a tribute at the 2019 Ride.

Margaret is now writing her memoir to share her story to a wider audience. "I have no idea why I'm still alive, but the least I can do is try to help other people in the same situation. I want to give back and share my story so other people can feel hope." 😢

Donor lists online: The PMCF. ca/AR2019



FINANCIAL

5-Year Overview

Each year, The Princess Margaret Cancer Foundation reports on the funds it raises and stewards in two ways: via Audited Financial Statements (AFS) online at www.thepmcf.ca, and via the standard CRA T3010 form required of all not-for-profit organizations and found on the CRA website at www.canada.ca/en/services/taxes/charities.html. While both formats utilize the same financial information, the Foundation's AFS provides a more detailed look to better assess and control our financial performance.

Statement of Revenue, Expenses a	nd Chang	es in Fun	d Balanc	es (\$ Th	nousands)
Year ended March 31	2015	2016	2017	2018	2019
Gross Fundraising Revenue	94,340	95,815	95,202	98,590	91,822
Direct Fundraising Expenses ¹	(16,223)	(16,793)	(14,990)	(16,237)	(16,676)
Net Fundraising	78,117	79,022	80,212	82,353	75,146
Gross Lottery Revenue	70,899	70,947	72,334	78,897	88,239
Direct Lottery Expenses	(47,145)	(46,153)	(44,640)	(49,170)	(54,627)
Net Lottery	23,754	24,794	27,694	29,727	33,612
Net Fundraising and Lottery Revenue	101,871	103,816	107,906	112,080	108,758
Investment Income (Loss)	48,029	(1,660)	45,006	31,561	36,964
Net Revenue, including Investment Income	149,900	102,156	152,912	143,641	145,722
General Fundraising and Administrative Expenses ²	10,122	10,724	11,287	12,467	14,925
Excess of Revenue over Expenses before Grants	139,778	91,432	141,625	131,174	130,797
Grants to Princess Margaret Cancer Centre					
Building	11,923	3,048	3,724	8,552	9,635
Research, Education and Patient Care	75,158	85,276	89,118	95,928	93,169
Equipment	8,395	8,137	9,618	2,083	1,868
	95,476	96,461	102,460	106,563	104,672
Excess (Deficiency) of Revenue over Expenses and Grants for the year	44,302	(5,029)	39,165	24,611	26,125
Fund Balances					
Endowments	245,998	233,837	250,297	271,911	294,553
Restricted	247,181	253,402	271,819	269,782	276,936
General	9,944	10,855	15,143	20,177	16,506
	503,123	498,094	537,259	561,870	587,995
Held By University of Toronto (as at April 30)	14,525	14,015	15,337	15,689	15,824
Total Capital	517,648	512,109	552,596	577,559	603,819

^{1.} Direct fundraising expenses represent costs for logistics, marketing and other expenses directly related to fundraising activities, including our major events such as Enbridge Ride to Conquer Cancer, OneWalk to Conquer Cancer and our Direct Marketing programs.

^{2.} General fundraising and administrative expenses are the overhead costs associated with running Foundation operations.



SUMMARIES

Fiscal 2019

The Princess Margaret Cancer Foundation is passionate about impact, efficient fundraising and effective stewardship to ensure we can achieve our collective vision to Conquer Cancer In Our Lifetime.

Fulfilling our Mission

Our mission is to raise and steward funds to deliver breakthrough research, exemplary teaching, and compassionate care at Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world.


Based on reported net fundraising revenue and lottery revenue (\$108.8 million):



Grants provided to Princess Margaret Cancer Centre (\$104.7 million):



Beyond funds granted this year (\$104.7 million), the Foundation has multi-year research and clinical commitments in progress at Princess Margaret Cancer Centre.



Distinct revenue streams

Gross revenue (excluding investment income) of \$180.0 million disclosed in the CRA T3010 form is composed of two distinct revenue streams: fundraising revenue and lottery revenue. Cost ratios associated with these streams are treated differently by the CRA.

Total gross fundraising revenue \$180.0 million

Fundraising revenue

\$91.8 million	gross fundraising revenue	
\$16.7 million	fundraising expenses	18.2%
\$75.1 million	net fundraising revenue	

Direct fundraising expenses include costs for logistics, marketing, and other costs directly related to strategic events and annual programs

Lottery revenue

	\$88.2 million	gross lottery revenue
37.5%	\$33.1 million	lottery prizes
24.4%	\$21.5 million	marketing and other expenses
38.1%	\$33.6 million	net lottery revenue

The PMCF lottery net revenue return of 38.1% compares favourably to the industry average return of 32.0% based on the three largest charitable lotteries in Canada. The PMCF lottery cost ratio of 61.9% is substantially lower than CRA acceptable guidelines (70.0%+).

Fundraising efficiency measure

The PMCF raised \$1.39 million per full-time employee, making it one of the most efficient and effective charities in Canada.





= \$108.8 million net revenue

Full financials online: The PMCF. ca/AR2019

RESEARCH CHAIRS

A Chair is the highest honour in academic life, prestigious for Chairholder and donor alike. Our Chairholders are recognized internationally for superior academic achievement, experience and success in teaching and research.

CHAIRS	CHAIRHOLDERS	
AMGEN Chair in Cancer Research Fund	Dr. Robert Rottapel	
Bartley-Smith Wharton Chair in Radiation Oncology	Dr. John Waldron	
Daniel E. Bergsagel Chair in Medical Oncology	Dr. Amit M. Oza	
Molly and David Bloom Chair in Multiple Myeloma Research	Dr. Donna Reece	
BMO Financial Group Chair in Precision Genomics	Dr. Lillian Siu	
Alan B. Brown Chair in Molecular Genomics	Dr. Geoffrey Liu	
Ronald N. Buick Chair in Oncology Research	Dr. Christopher J. Paige	
Butterfield/Drew Chair in Cancer Survivorship Research	Dr. Jennifer Jones	
M. Qasim Choksi Chair in Lung Cancer Translational Research	Dr. Ming S. Tsao	
Richard H. Clark Chair in Cancer Medicine	Dr. Mary Gospodarowicz	
J. Douglas Crashley Chair in Gynecologic Cancer Research Fund	Dr. Sarah Ferguson	
Dr. Mariano Antonio Elia Chair in Head and Neck Cancer Research	To be appointed	
Anna-Liisa Farquharson Chair in Kidney Cancer Research	Dr. Antonio Finelli	
Orey and Mary Fidani Family Chair in Radiation Physics	Dr. David Jaffray	
Gattuso Chair in Breast Surgical Oncology Fund	Dr. David R. McCready	
Peter and Shelagh Godsoe Chair in Radiation Medicine	Dr. Fei-Fei Liu	
JCB Grant Chair in Oncologic Pathology	Dr. Runjan Chetty	
K. Y. Ho Chair in Prostate Cancer Research	To be appointed	
Kirchmann Family Chair in Neuro-Oncology Research	Dr. Warren Mason	
Lee K. and Margaret Lau Chair in Breast Cancer Research	To be appointed	
Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care	Dr. Gary M. Rodin	
Wilfred G. Lewitt Chair in Pancreatic Cancer Research	Dr. Jennifer J. Knox	
The Love Chair in Prostate Cancer Prevention Research Fund	Dr. Neil Fleshner	
The Addie MacNaughton Chair in Thoracic Radiation Oncology	Dr. Andrea Bezjak	
Gullane Family/O'Neil Family Chair in Otolaryngology/Head & Neck Surgery	Dr. Ralph W. Gilbert	
Philip S. Orsino Chair in Leukemia Research	Dr. Mark D. Minden	
OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development	Dr. Natasha B. Leighl	
RBC Chair in Nursing Oncology, Research and Education	Dr. Doris Howell	
Kevin and Sandra Sullivan Chair in Surgical Oncology	Dr. Jonathan C. Irish	
Joey and Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research	Dr. Gang Zheng	
Neekend to End Breast Cancer Chair in Breast Cancer Research	Dr. Tak W. Mak	
Nestaway Chair in Ovarian Cancer Research	To be appointed	
The Robert E. Wharton Chair in Head and Neck Surgery	Dr. Patrick J. Gullane	
The Robert E. Wharton Chair in Reconstructive Plastic Surgery	Dr. Stefan O. Hofer	
JOINT CHAIRS AT UNIVERSITY HEALTH NETWORK	CHAIRHOLDERS	
Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation	To be Appointed	
The Alan and Susan Hudson Chair in Neuro-Oncology	Dr. Fred Gentili	
Pearson/Ginsberg Chair in Thoracic Surgical Oncology	Dr. Shaf Keshavjee	
Scotiabank Group Director's Chair, Centre for Medical Discovery	Dr. David Brooks	
Fleck/Tanenbaum Chair in Prostatic Diseases	Dr. John Trachtenberg	
Scott Taylor Chair in Lung Cancer Research	Dr. Frances A. Shepherd	
J. Gerald Scott/David G. Whitmore Chair in Hematology and Gene Therapy Research	To be Appointed	



BOARD OF DIRECTORS

The Princess Margaret Cancer Foundation

April 1, 2018 to March 31, 2019

Janice Fukakusa

Board Chair Corporate Director

Mark Allison

VP Real Estate Performance Auto Group

Terry Bacinello

President TZB Holdings

Stephen Bear*

Director Emeritus McKinsey & Company

Rohit Bhapkar

Senior Partner McKinsey & Company

Sean Boyd

CEO

Agnico Eagle Mines Limited

J-F Courville

CFO

Wealthsimple for Advisors

David Engel

President and Founder Innovative

Marnie Escaf

Senior VP, UHN **Executive Lead** Princess Margaret Cancer Centre

Jack Fleischmann*

Communications Consultant

Harry Goldgut

Vice-Chair

Infrastructure and Renewable Power Brookfield Asset Management Inc.

Dr. Mary Gospodarowicz

Medical Director Princess Margaret Cancer Centre

Andrew L. Hoffman

Chief Executive Officer CentreCourt Developments Inc.

Candace Innes

Marketing Consultant

Andrew Irvine

Head

Canadian Business Banking **BMO** Financial Group

Glenn Ives

Past Chair & Senior Partner Deloitte Canada

Christina Kramer

Senior Executive Vice-President & Group Head, Personal & Small Business Banking Canada

Stacey Madge

President & Country Manager Visa Canada

Karen Maidment

Corporate Director TD Bank, TD Ameritrade

Bill Richardson

Senior Partner Baker & McKenzie LLP

Richard Rooney

President

Burgundy Asset Management

Annie Ropar

CFO & CAO

Canada Infrastructure Bank

Larry Rosen

Chairman & CEO Harry Rosen Inc.

Dr. Aaron Schimmer

Research Director Princess Margaret Cancer Centre

Jürgen Schreiber

Senior Managing Director Katz Group

David R. Shaw

Chairman

LHH/Knightsbridge and Axsium Group

Duncan Sinclair

Chairman

Deloitte Canada & Chile

Kevin Smith

President & CEO University Health Network

Jochen Tilk

Corporate Director

Stuart Waugh

Managing Director & Managing Partner Northleaf Capital Partners

Michael Worb

Founder & CEO Accompass

Dr. Bradly Wouters

Executive Vice-President Science and Research University Health Network

For the full list of committee members visit: ThePMCF.ca/AR2019

Our thanks are also extended to the following individuals from our community of supporters who also serve on committees of The Princess Margaret Cancer Foundation.

Cecile Chung **Bob Dorrance** Tom Ehrlich Stephen Goldhar Mark Hanrahan

Marianne Harris Helen Mallovy Hicks Lorraine Kirchmann Neville Kirchmann Maureen Shaughnessy Kitts Angela McDonald Wendy Posluns Tina Tehranchian Michael S. Wilson **Betsy Wright**

^{*}Board term ended at September 2018 Annual General Meeting

BOARD OF DIRECTORS UHN

April 1, 2018 to March 31, 2019

BOARD OFFICERS

Chair:

Brian J. Porter

Vice-Chairs:

Ross Baker

Dean Connor

Lawrence Pentland

Barbara Stymiest

Appointed

President:

Kevin Smith

Board Secretary:

Kevin Smith

BOARD MEMBERS

Independent Trustees (Voting)

Brian J. Porter

Chair

Ross Baker

Dean Connor

Todd Halpern

Stu Kedwell

Doug McGregor

Peter Menkes

Lawrence Pentland

Janet Rossant

Shirlee Sharkey

Barbara Stymiest

Peter Wallace

Jaime Watt

Cornell Wright

U of T Representatives (Voting)

Cheryl Regehr

Vice-President & Provost

Trevor Young

Dean of Medicine

Ex-officio Trustees (Non-Voting)

Kevin Smith

Chief Executive Officer

Joy Richards

Chief Health Professions

Fei-Fei Liu

Medical Advisory Committee

Eric Horlick

Medical Staff Association

President

Raj Kothari

Chair of the Toronto General & Western Hospital Foundation

Janice Fukakusa

Chair of The Princess Margaret **Cancer Foundation**

A HEALTHIER WORLD:

UHN'S 2019-23 STRATEGIC PLAN

UHN's Strategic Plan is our guide for making important choices to advance care, research and education. Built on the trust of patients and passion of TeamUHN, our Strategic Priorities will move us toward our vision of A Healthier World

Read the full report: **UHNstrategicplan.ca**





THE PRINCESS MARGARET IS TRANSFORMING CANCER CARE



Margaret Imai-Compton has climbed the highest mountain in the Alps, reached the top of the Canadian Rockies and trekked the Himalayas.


When the 65-year-old Toronto woman was presented with a different kind of challenge five years ago – Stage 3C ovarian cancer – she approached it the same way she would any climb.

Read Margaret's full story: PMclinicaltrials.ca











5 FACTS ABOUT THE PRINCESS MARGARET



Home to Canada's most comprehensive immune therapy program

Our single-site radiation medicine program is one of the world's largest & most advanced



We have the largest first-in-human cancer clinical trial programs in the country



Ranks 2nd in the world for percentage of research papers published in high-impact oncology journals



A world leader in cancer stem cell research

ThePMCF.ca/AR2019

The Princess Margaret Cancer Foundation **UHN**

Office/Courier Address:

700 University Avenue, 10th Floor, Toronto, ON M5G 1Z5 T: 416.946.6560 / 1.866.224.6560 F: 416.946.6563

Mailing Address:

610 University Avenue, Toronto, ON M5G 2M9

Follow or Like us on social media:









